BACKGROUND: Hemorrhage coupled with coagulopathy remains the leading cause of preventable in-hospital deaths among trauma patients. Use of a transfusion protocol with a predefined ratio of 1:1:1 (1 each of red blood cells [RBC], frozen plasma [FP] and platelets) has been associated with improved survival in retrospective studies in military and civilian settings, but such a protocol has its challenges and may increase the risk of respiratory complications. We conducted a randomized controlled trial to assess the feasibility of a 1:1:1 transfusion protocol and its effect on mortality and complications among patients with severe trauma. METHODS: We included 78 patients seen in a tertiary trauma centre between July 2009 and October 2011 who had hypotension and bleeding and were expected to need massive transfusion (≥ 10 RBC units in 24 h). We randomly assigned them to either the fixed-ratio (1:1:1) transfusion protocol (n = 40) or to a laboratory-results-guided transfusion protocol (control; n = 38). The primary outcome, feasibility, was assessed in terms of blood product ratios and plasma wastage. Safety was measured based on 28-day mortality and survival free of acute respiratory distress syndrome. RESULTS: Overall, a transfusion ratio of 1:1:1 was achieved in 57% (21/37) of patients in the fixed-ratio group, as compared with 6% (2/32) in the control group. A ratio of 1:1 (RBC:FP) was achieved in 73% (27/37) in the fixed-ratio group and 22% (7/32) in the control group. Plasma wastage was higher with the intervention protocol (22% [86/390] of FP units v. 10% [30/289] in the control group). The 28-day mortality and number of days free of acute respiratory distress syndrome were statistically similar between the groups. INTERPRETATION: The fixed-ratio transfusion protocol was feasible in our study, but it was associated with increased plasma wastage. Larger randomized trials are needed to evaluate the efficacy of such a protocol in trauma care. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT00945542.
RCT Entities:
BACKGROUND:Hemorrhage coupled with coagulopathy remains the leading cause of preventable in-hospital deaths among traumapatients. Use of a transfusion protocol with a predefined ratio of 1:1:1 (1 each of red blood cells [RBC], frozen plasma [FP] and platelets) has been associated with improved survival in retrospective studies in military and civilian settings, but such a protocol has its challenges and may increase the risk of respiratory complications. We conducted a randomized controlled trial to assess the feasibility of a 1:1:1 transfusion protocol and its effect on mortality and complications among patients with severe trauma. METHODS: We included 78 patients seen in a tertiary trauma centre between July 2009 and October 2011 who had hypotension and bleeding and were expected to need massive transfusion (≥ 10 RBC units in 24 h). We randomly assigned them to either the fixed-ratio (1:1:1) transfusion protocol (n = 40) or to a laboratory-results-guided transfusion protocol (control; n = 38). The primary outcome, feasibility, was assessed in terms of blood product ratios and plasma wastage. Safety was measured based on 28-day mortality and survival free of acute respiratory distress syndrome. RESULTS: Overall, a transfusion ratio of 1:1:1 was achieved in 57% (21/37) of patients in the fixed-ratio group, as compared with 6% (2/32) in the control group. A ratio of 1:1 (RBC:FP) was achieved in 73% (27/37) in the fixed-ratio group and 22% (7/32) in the control group. Plasma wastage was higher with the intervention protocol (22% [86/390] of FP units v. 10% [30/289] in the control group). The 28-day mortality and number of days free of acute respiratory distress syndrome were statistically similar between the groups. INTERPRETATION: The fixed-ratio transfusion protocol was feasible in our study, but it was associated with increased plasma wastage. Larger randomized trials are needed to evaluate the efficacy of such a protocol in trauma care. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT00945542.
Authors: John B Holcomb; Don Jenkins; Peter Rhee; Jay Johannigman; Peter Mahoney; Sumeru Mehta; E Darrin Cox; Michael J Gehrke; Greg J Beilman; Martin Schreiber; Stephen F Flaherty; Kurt W Grathwohl; Phillip C Spinella; Jeremy G Perkins; Alec C Beekley; Neil R McMullin; Myung S Park; Ernest A Gonzalez; Charles E Wade; Michael A Dubick; C William Schwab; Fred A Moore; Howard R Champion; David B Hoyt; John R Hess Journal: J Trauma Date: 2007-02
Authors: Donald M Arnold; Karen E A Burns; Neill K J Adhikari; Michelle E Kho; Maureen O Meade; Deborah J Cook Journal: Crit Care Med Date: 2009-01 Impact factor: 7.598
Authors: Eileen M Bulger; Gregory J Jurkovich; Avery B Nathens; Michael K Copass; Sandy Hanson; Claudette Cooper; Ping-Yu Liu; Margaret Neff; Asaad B Awan; Keir Warner; Ronald V Maier Journal: Arch Surg Date: 2008-02
Authors: Matthew A Borgman; Philip C Spinella; Jeremy G Perkins; Kurt W Grathwohl; Thomas Repine; Alec C Beekley; James Sebesta; Donald Jenkins; Charles E Wade; John B Holcomb Journal: J Trauma Date: 2007-10
Authors: Christopher W Snyder; Jordan A Weinberg; Gerald McGwin; Sherry M Melton; Richard L George; Donald A Reiff; James M Cross; Jennifer Hubbard-Brown; Loring W Rue; Jeffrey D Kerby Journal: J Trauma Date: 2009-02
Authors: Bryan A Cotton; Oliver L Gunter; James Isbell; Brigham K Au; Amy M Robertson; John A Morris; Paul St Jacques; Pampee P Young Journal: J Trauma Date: 2008-05
Authors: Geoffrey R Nunns; Ernest E Moore; Gregory R Stettler; Hunter B Moore; Arsen Ghasabyan; Mitchell Cohen; Benjamin R Huebner; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: Surgery Date: 2018-04-27 Impact factor: 3.982
Authors: John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle Journal: JAMA Date: 2015-02-03 Impact factor: 56.272
Authors: Deborah J Novak; Yu Bai; Rhonda K Cooke; Marisa B Marques; Magali J Fontaine; Jerome L Gottschall; Patricia M Carey; Richard M Scanlan; Eberhard W Fiebig; Ira A Shulman; Janice M Nelson; Sherri Flax; Veda Duncan; Jennifer A Daniel-Johnson; Jeannie L Callum; John B Holcomb; Erin E Fox; Sarah Baraniuk; Barbara C Tilley; Martin A Schreiber; Kenji Inaba; Sandro Rizoli; Jeanette M Podbielski; Bryan A Cotton; John R Hess Journal: Transfusion Date: 2015-03-30 Impact factor: 3.157
Authors: Matthew J Delano; Sandro B Rizoli; Shawn G Rhind; Joseph Cuschieri; Wolfgang Junger; Andrew J Baker; Michael A Dubick; David B Hoyt; Eileen M Bulger Journal: Shock Date: 2015-07 Impact factor: 3.454
Authors: Hunter B Moore; Ernest E Moore; Michael P Chapman; Kevin McVaney; Gary Bryskiewicz; Robert Blechar; Theresa Chin; Clay Cothren Burlew; Fredric Pieracci; F Bernadette West; Courtney D Fleming; Arsen Ghasabyan; James Chandler; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: Lancet Date: 2018-07-20 Impact factor: 79.321
Authors: Sarah Baraniuk; Barbara C Tilley; Deborah J del Junco; Erin E Fox; Gerald van Belle; Charles E Wade; Jeanette M Podbielski; Angela M Beeler; John R Hess; Eileen M Bulger; Martin A Schreiber; Kenji Inaba; Timothy C Fabian; Jeffrey D Kerby; Mitchell Jay Cohen; Christopher N Miller; Sandro Rizoli; Thomas M Scalea; Terence O'Keeffe; Karen J Brasel; Bryan A Cotton; Peter Muskat; John B Holcomb Journal: Injury Date: 2014-06-10 Impact factor: 2.586